



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 95/04532
A61K 31/34, 31/35, 31/335, 31/38, 31/275, 31/655, C07D 317/44, 315/00, 307/02, C07C 211/00, 117/00, 229/00, 69/00			(43) International Publication Date:	16 February 1995 (16.02.95)
(21) International Application Number:	PCT/US94/08845			
(22) International Filing Date:	5 August 1994 (05.08.94)			
(30) Priority Data:	08/102,436	5 August 1993 (05.08.93)	US	
(71) Applicant:	DISCOVERY THERAPEUTICS INC. [US/US]; Suite E-17, 2028 Dabney Road, Richmond, VA 23230-3311 (US).			
(72) Inventors:	SLEEVY, Mark, C.; 2612 Olde Stone Road, Mid- lothian, VA 23113 (US). MINASKANIAN, Gevork; 11701 Lockport Terrace, Richmond, VA 23233 (US). MOSES, L., Meredith; 5003 Eddings Drive, Glen Allen, VA 23060 (US).			
(74) Agents:	ESMOND, Robert, W. et al.; Sterne, Kessler, Gold- stein & Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).			

(54) Title: SUBSTITUTED 2-AMINOTETRALINS

(57) Abstract

Optically active or racemic compounds represented by formula (I) wherein R₁, R₂, R₃, R₅ and n are defined as in the specification, and pharmaceutically acceptable salts thereof. These compounds are useful for alleviating Parkinsonism, glaucoma, hyperprolactinemia and for inducing weight loss in mammals.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


Substituted 2-Aminotetralins

Field of the Invention

This invention relates generally to substituted 2-aminotetralins, to processes for preparing such compounds and methods for administering compositions of such compounds in amounts effective to induce a desired physiological response in mammals. More particularly, the invention relates to compounds for therapeutic use, in particular in treating central nervous, endocrine and ophthalmic disorders. The compounds of this invention are useful for alleviating Parkinsonism, glaucoma, hyperprolactinemia, and for inducing weight loss in mammals.

Background of the Invention

It is known that various hydroxylated 2-aminotetralins of the general formula



where R₁ and R₂ are saturated alkyl groups and n is 1 or 2, are dopamine receptor agonists [McDermed et al., J. Med. Chem. 18, 362 (1975); 15 McDermed et al., J. Med. Chem. 19, 547 (1976); Hacksell et al., J. Med. Chem. 22, 1469 (1979)].

It is also known that compounds where n is 1, R₁ is a saturated alkyl group, and R₂ is various functionalized alkyl groups have been shown to be dopamine receptor agonists [Seiler et al., U.S. Patent No. 4,410,519; Seiler et al., J. Med. Chem. 29, 912 (1986)].

Horn, in U.S. Patent No. 4,564,628, has disclosed that various hydroxylated 2-aminotetralins with aralkyl substituents are useful as dopamine and D-2 receptor agonists for the treatment of disorders of the central nervous

system as applied to Parkinson's disease and related disorders, hypertension and hyperprolactinemia.


U.S. Patent No. 4,722,933 further discloses that certain aralkyl substituted 2-aminotetralins are useful in lowering intraocular pressure in mammals and can be beneficial for alleviating the symptoms of glaucoma.

Santangelo, in European Patent Application No. 0321968, describes certain aminotetralins with aryloxyalkyl substituents as having cardiovascular activity.

The need exists for more and better drugs useful in the treatment of central nervous, ophthalmic and endocrine disorders in humans and other animals. Especially, the need exists for drugs that cause a minimum of undesirable side effects at therapeutic dosages and for drugs that do not show tolerance in the subject upon prolonged administration, but are capable of advantageously affecting the dopamine receptor sites without providing an undesirable physiological response.


Summary of the Invention

There has now been discovered certain novel compounds having dopaminergic activity and having the structural formula




where R₂ is OA and R₃ is selected from the group consisting of H and OA; where A is H or is selected from the group consisting of hydrocarbyl radicals comprising between 1 and 3 carbon atoms, as well as

-3-



10 R_4 is selected from the group consisting of alkyl and aromatic residues
 having from 1 to 20, preferably from 1 to 12, carbon atoms, for example,
 alkyl, optionally substituted with aromatic residues, and aromatic residues
 optionally substituted with alkyl radicals; n is an integer from 1 to 4; R_5 is
 an unbranched alkyl chain having from 1 to 3 carbon atoms or a
 cyclopropylmethyl radical; and R_1 is alkoxy, cycloalkoxy and a cyclic ether
 15 of the formula



where m is an integer from 3 to 5; with the provision that when R_1 is alkoxy,
 then R_3 cannot be H.

20 It is essential that the compounds in the present invention be an
 optically active compound or racemic mixture thereof having substantial
 affinity and selectivity for binding to dopamine D-2 receptors, e.g. in a
 human.

Description of Preferred Embodiments

Alkyl means straight or branched hydrocarbon alkyl having 1 to 20
 25 carbon atoms and includes, for example, methyl, ethyl, propyl, isopropyl,
 butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl,

hexyl, heptyl, octyl, 2-ethylhexyl, 1,1,3,3-tetramethylbutyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, and eicosyl;

Alkoxy means straight-chain or branched hydrocarbon alkoxy having 1 to 5 carbon atoms and includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, secondary butoxy, tertiary butoxy, pentyloxy, and isopentyloxy;


Cycloalkoxy means that the cycloalkyl moiety is a cyclic alkyl group having 3 to 5 carbon atoms;

Aromatic residues means phenyl or naphthyl or substituted phenyl or substituted naphthyl which are phenyl or naphthyl substituted by at least one substituent selected from the group consisting of halogen (chlorine, bromine, fluorine or iodine), amino, nitro, hydroxy, and alkyl.

It should be noted that the term "hydrocarbyl" includes both the above-defined alkyl and aromatic residues.

Further, the group $-(\text{CH}_2)_n-$, as shown in the structural formula of the compounds of the present invention, includes both linear and branched moieties.

The compounds used in the present invention are selected from the group of stereoisomers or mixtures thereof of compounds having dopaminergic activity represented by the formula



where R_2 is OA and R_3 is selected from the group consisting of H and OA; where A is H or is selected from the group consisting of hydrocarbyl radicals comprising between 1 and 3 carbon atoms, as well as

-5-


$\begin{array}{c} \text{O} \\ \parallel \\ \text{---C---R}_4, \quad \begin{array}{c} \text{O} \\ \parallel \\ \text{---C---NHR}_4, \quad \begin{array}{c} \text{O} \\ \parallel \\ \text{---C---N}(\text{R}_4)_2, \quad \text{and} \quad \begin{array}{c} \text{O} \\ \parallel \\ \text{---C---OR}_4, \end{array} \end{array}$ with
 the proviso that when R_3 is OA, then R_2 and R_3 may be bonded together

5

to form the group $\text{---O---CH}_2\text{---O---}$ or ---O---C---O--- .

10

R_4 is selected from the group consisting of alkyl and aromatic residues having from 1 to 20, preferably from 1 to 12, carbon atoms, for example, alkyl, optionally substituted with aromatic residues, and aromatic residues optionally substituted with alkyl radicals; n is an integer from 1 to 4; R_5 is an unbranched alkyl chain comprising from 1 and 3 carbon atoms or a cyclopropylmethyl radical; R_1 is alkoxy, cycloalkoxy and a cyclic ether of the formula



15

where m is an integer from 3 to 5; with the proviso that when R_1 is alkoxy, then R_3 cannot be H; and pharmaceutically-acceptable salts thereof.

20

Preferably, R_3 is OA and A is H, and more preferably R_4 is an alkyl or aryl radical, for example, methyl, t-butyl, pentyl, nonyl, undecyl, or phenyl.

The more preferred groups represented by R_1 are ethoxy, propoxy, isopropoxy, butoxy, s-butoxy, iso-butoxy, and t-butoxy.

25

In the more preferred compounds for use in the present invention, n is 2 or 3 and R_3 is OA; and most preferably A is H, R_5 is propyl, and the stereochemical configuration of the carbon atom in the tetralin ring bearing nitrogen is S.

It is essential that the compounds herein be an optically active or racemic mixture capable of binding selectively to dopamine D-2 receptors, e.g., in a human. In particular, (S)-6-[[2-(1,1-dimethylethoxy)ethyl] propylamino]-5,6,7,8-tetrahydro-1,2-naphthalenediol is an especially preferred compound because of its high affinity, selectivity, specificity, and functional potency at dopamine D-2 receptors, as well as its high in vivo functional potency. Due to their pharmacological profile, it is believed that the compounds herein will be useful in the treatment of central nervous, ophthalmic, and endocrine disorders. In particular, it is believed that the compounds herein are useful in the treatment of such conditions in humans as Parkinsonism, elevated intraocular pressure, and for inducing weight loss in humans and other mammals.

Particularly preferred compounds are as follows: (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol, (S)-6-[[2-(ethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-1,2-naphthalenediol, (S)-5,6,7,8-tetrahydro-6-[[2-(propoxy)ethyl]propylamino]-1,2-naphthalenediol, (S)-6-[[2-(butoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-1,2-naphthalenediol, (S)-6-[[2-(1,1-dimethylethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-1,2-naphthalenediol, (6S)-5,6,7,8-tetrahydro-6-[[tetrahydro-3-furanyl)methyl]propylamino]-1-naphthalenol, (S)-6,7,8,9-tetrahydro-N-[2-(1-methylethoxy)ethyl]-N-propylnaphtho[1,2-d]-1,3-dioxol-7-amine, (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol diacetate, (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol dihexanoate, (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol cyclic carbonate, and (S)-6-[[2-(1,1-dimethylethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-1,2-naphthalenediol diacetate.

Methods for preparing the S-enantiomers of the compounds of the present invention employ S-5-methoxy-2-n-propylaminotetralin disclosed in U.S. Patent No. 4,968,837, or S-5-methoxy-2-aminotetralin disclosed in

McDermed et al., J. Med. Chem. 19(4), 547-9 (1976), which are hereby incorporated by reference.

5

For purposes of this invention, designation of the S-enantiomer shall mean that the S-enantiomer is present in excess of the R-enantiomer. Preferably, the mixture is greater than 90 mole-percent of the S-enantiomer. Most preferably, the S-enantiomer is substantially pure, i.e., greater than 99 mole-percent.

10

This invention provides a method of treatment which comprises inducing a response at D-2 receptors by administering a therapeutically-effective amount of one of the foregoing compounds to the patient. In general, a pharmacologically-effective daily dose can be from 0.001 mg./kg. to 100 mg./kg. per day, and preferably from about 0.005 mg./kg. to 10 mg./kg. per day, bearing in mind, of course that in selecting the appropriate dosage, in any specific case, consideration must be given to the patient's weight, general health, metabolism, age, and other factors which influence response to the drug. A particularly preferred dose is 0.005 mg./kg. (subcutaneous) per day.

20

Another embodiment of this invention is the provision of pharmaceutical compositions in dosage unit form which comprise from about 0.05 to 500 mg. of a compound of the above formula.

25

The pharmaceutical composition may be in a form suitable for oral use, for example, as tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, antioxidants, and preserving agents in order to provide a pharmaceutically elegant and palatable preparation. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically-acceptable excipients which are suitable for manufacture of tablets. These excipients may be, for example, inert diluents, for example,

calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, for example, maize starch, or alginic acid; binding agents, for example, starch, gelatin, or acacia; and lubricating agents, for example, magnesium stearate, stearic acids, or talc. 5 The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for 10 example, calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with an oil medium, for example, arachis oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active compound in admixture with excipients suitable for the manufacture of aqueous suspensions. Such 15 excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, and gum acacia; dispersing or wetting agents may be naturally-occurring phosphatides, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of 20 ethylene oxide with long chain aliphatic alcohols, for example, heptadecethylenoxycycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, for example, polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for 25 example, polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ethyl-, n-propyl-, or p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin, or sodium or 30 calcium cyclamate.

5 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents may also be present.

10 Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, preservative, flavoring or coloring agent. The pharmaceutical compositions may be in the form of a sterile injectable aqueous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile 15 injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.

20 The pharmaceutical compositions may be tableted or otherwise formulated so that for every 100 parts by weight of the composition there are present between 5 and 95 parts by weight of the active ingredient. The dosage unit form will generally contain between about 0.05 mg. and about 100 mg. 25 of the active ingredient of the formula stated above.

25 From the foregoing formulation discussion, it is apparent that the compositions of this invention can be administered orally or parenterally. The term parenterally as used herein includes subcutaneous injection, intravenous, intramuscular, or intrasternal injection or fusion techniques. The compositions can also be administered transdermally with the optional use of a transdermal penetration enhancer such as Azone® (as described in U.S. Patent No. 4,405,616) in a variety of formulations such as patches, topical creams, or solutions as well known in the art.

30 To illustrate the manner in which the invention may be carried out, the following examples are given. It is understood, however, that the examples

-10-


are for the purpose of illustration and the invention is not to be regarded as limited to any of the specific materials or conditions therein.

Examples

5 Compounds of the present invention wherein R₂ and R₃ are both OH (general formula 1) can be prepared as shown below (Method A). The process is described in detail for Example #1. For all the following methods, the required triflates [R₆OSO₂CF₃, wherein R₆ is defined as R₁-(CH₂)_n-] are prepared in situ from alcohols obtained commercially or available by methods previously published in the literature.

-11-

Method A



*Method A - Detailed Example**Preparation of (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol, hydrochloride (Example 1)*

5 A. *(S)-5,6,7,8-Tetrahydro-6-propylamino-1-naphthalenol, hydrobromide.* A mixture of (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-naphthalenamine (10.0 g, 0.0391 mol) as the HCl salt, or its corresponding free base, was heated at reflux in 48% hydrobromic acid (150 mL) for a period of two to three hours. The solution was cooled to room temperature and the resulting solid was collected by filtration. Drying under high vacuum 10 at 60°C gave 10.7 g of the product (96% yield).

10 B. *(S)-N-(1,2,3,4-Tetrahydro-5-hydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester.* A stirring suspension of (S)-6-propylamino-5,6,7,8-tetrahydro-1-naphthalenol (7.34 g, 0.0257 mol) in water (100 mL) was cooled in an ice bath and sodium bicarbonate (8.49 g, 0.101 mol) was added. This suspension was stirred for fifteen minutes then benzyl chloroformate (4.50 g, 0.0264 mol) was added dropwise. The mixture was stirred for fifteen minutes and then allowed to come to room temperature. Ether (100 mL) was added and the mixture was stirred overnight. The layers 15 were separated and the aqueous layer was extracted with ether. The combined organic layers were washed twice with saturated aqueous sodium bicarbonate, once with water, twice with dilute hydrochloric acid, once with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated under reduced pressure to give 7.09 g (81% yield) of product as 20 a yellow solid.

25 C. *(S)-N-(6-Formyl-1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester.* A solution of (S)-N-(1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester (7.09 g, 0.0209 mol) in dry toluene (400 mL) was stirring under a nitrogen atmosphere at room temperature and ethylmagnesium bromide

(7.3 mL of a 3.0 M solution in ether, 0.0219 mol) was added. The suspension was stirred for fifteen minutes and then a portion of the solvent (50 mL) was removed by distillation. After the suspension was cooled to room temperature, paraformaldehyde (1.57 g, 0.0523 mol) was added, followed by hexamethylphosphoramide (3.75 g, 0.0209 mol). The solution was heated at reflux for three hours and poured into aqueous 1N hydrochloric acid (800 mL) with stirring. Ether was added and the layers were separated. The aqueous layer was extracted again with ether. The combined organic extracts were washed three times with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated under reduced pressure. Column chromatography of the oily residue on silica eluting with ethyl acetate-light pet ether (1:4) afforded 6.96 g of product (91% yield).

D. (S)-N-(1,2,3,4-Tetrahydro-5,6-dihydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester. A solution of (S)-N-(6-formyl-1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester (6.96 g, 0.0190 mol) in methanol (25 mL) was stirred at room temperature, then sodium hydroxide (19.0 mL of a 1N aqueous solution, 0.0190 mol) and water (25 mL) were added. A stream of nitrogen was bubbled through the solution for thirty minutes. Hydrogen peroxide (2.12 mL of a 30% aqueous solution, 0.0206 mol) was added dropwise and the mixture was stirred under nitrogen for ninety minutes. Aqueous 1N hydrochloric acid (16 mL) and ether were added. The layers were separated and the aqueous layer was extracted with ether. The combined organic layers were washed twice with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated under reduced pressure. Recrystallization of the residue from ethyl acetate-light pet ether gave 5.29 g (78% yield) of product as a white solid.

E. Mixture of (S)-N-[5-[dimethylethyl]silyloxy]-6-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-N-propylcarbamic acid and (S)-N-[6-[dimethyl(1,1-dimethylethyl)silyloxy]-5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl]-N-propylcarbamic acid, phenylmethyl esters. A solution of (S)-

N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester (1.5 g, 0.00422 mol) in dry tetrahydrofuran (30 mL) was stirred under nitrogen and tert-butyldimethylsilyl chloride (1.40 g, 0.00929 mol) was added, followed by imidazole (1.44 g, 0.0212 mol). The suspension was stirred at room temperature overnight. Water and ether were added and the layers were separated. The aqueous layer was extracted twice with ether and the combined organic layers were washed once with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. Column chromatography of the oily residue on silica eluting with ethyl acetate-light pet ether (1:9) yielded 1.54 g (78% yield) of the product mixture as a colorless oil.

F. Mixture of (S)-2-[dimethyl(1,1-dimethylethyl)silyloxy]-6-propylamino-5,6,7,8-tetrahydro-1-naphthalenol and (S)-1-[dimethyl(1,1-dimethylethyl)silyloxy]-6-propylamino-5,6,7,8-tetrahydro-2-naphthalenol. The mixture of (S)-N-[5-[dimethylethyl)silyloxy]-6-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl]-N-propylcarbamic acid and (S)-N-[6-[dimethyl(1,1-dimethylethyl)silyloxy]-5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl]-N-propylcarbamic acid, phenylmethyl esters (1.54 g, 0.00328 mol) in tetrahydrofuran (50 mL) was hydrogenated (40 psi) over 5% palladium on carbon for two hours. The catalyst was removed by filtration through a pad of Celite. The filtrate was concentrated under reduced pressure to give the oily product mixture which was used without additional purification.

25 G. *Mixture of (S)-2-[dimethyl(1,1-dimethylethyl)silyloxy]-6-[[2-(1-methylethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-1-naphthalenol and (S)-1-[dimethyl((1,1-dimethylethyl)silyloxy)-6-[[2-(1-methylethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-2-naphthalenol.* A solution of 2-(1-methylethoxy)ethanol (0.49 g, 0.00471 mol) in methylene chloride (10 mL) was cooled in an ice-acetone bath with stirring under nitrogen. Diisopropylethylamine (1.2 g, 0.00928 mol) was added, followed by trifluoromethanesulfonic anhydride (1.33 g, 0.00471 mol) and the solution was stirred for ten minutes. A solution of the mixture of (S)-2-[dimethyl(1,1-

dimethylethyl)silyloxy]-6-propylamino-5,6,7,8-tetrahydro-1-naphthalenol and (S)-1-[dimethyl(1,1-dimethylethyl)silyloxy]-6-propylamino-5,6,7,8-tetrahydro-2-naphthalenol in methylene chloride (15 mL) was added dropwise. The solution was allowed to come to room temperature and stirred overnight. 5 Water and ether were added and the layers were separated. The aqueous layer was extracted with ether and the combined organic layers were washed once with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. Column chromatography of the residue 10 on silica eluting with ethyl acetate-light pet ether (1:9) gave 0.56 g (40% yield) of the product mixture as a colorless oil.

H. *(S)-5,6,7,8-Tetrahydro-6-[[2-(1-methylethoxy)ethyl]-propylamino]-1,2-naphthalenediol, hydrochloride.* The oily mixture of (S)-2-[dimethyl(1,1-dimethylethyl)silyloxy]-6-[[2-(1-methylethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-1-naphthalenol and (S)-1-[dimethyl((1,1-dimethylethyl)silyloxy)-6-[[2-(1-methylethoxy)ethyl]propylamino]-5,6,7,8-tetrahydro-2-naphthalenol (0.56 g, 0.00133 mol) was dissolved in dry tetrahydrofuran (50 mL) and a stream of nitrogen was bubbled through the stirring solution for twenty minutes. 15 Tetrabutylammonium fluoride (3.92 mL of a 1.0 M solution in tetrahydrofuran, 0.00392 mol) was added and the solution (with nitrogen still bubbling) was stirred at room temperature for forty-five minutes. Water and ether were added and the layers were separated. The aqueous layer was extracted with ether and the combined organic layers were washed twice with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. Column chromatography of the residue on silica 20 eluting with ethyl acetate-light pet ether (1:1) afforded the oily free base of the product. This material was dissolved in ether and treated with ethereal hydrogen chloride. The mother liquor was decanted from the amorphous solid which separated and the solid was washed twice with additional ether. Drying 25 under high vacuum at 40°C overnight gave 0.2163 g (47% yield) of the product. 30

Table I summarizes compounds which are examples of the present invention prepared by Method A, in which R₂ and R₃ are both OH and R₅ is -CH₂CH₂CH₃:




Table I


5	Example	R ₆	Elemental Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
	1	-CH ₂ CH ₂ OCH(CH ₃) ₂	C ₁₈ H ₃₀ NO ₃ Cl	C: 62.87/63.05 H: 8.79/8.83 N: 4.07/3.89	-44.9 c=1.1
	2	-CH ₂ CH ₂ OCH ₂ CH ₃	C ₁₇ H ₂₈ NO ₃ Cl	C: 61.90/61.74 H: 8.56/8.50 N: 4.25/4.14	-52.6 c=0.82
	3	-CH ₂ CH ₂ OCH ₂ —	C ₁₉ H ₃₀ NO ₃ Cl	C: 64.12/64.10 H: 8.50/8.64 N: 3.94/3.84	-51.8 c=1.4
	4	-CH ₂ CH ₂ OCH ₃	C ₁₆ H ₂₆ NO ₃ Cl	C: 60.85/60.89 H: 8.30/8.40 N: 4.43/4.30	-57.4 c=1.1
10	5	-(CH ₂) ₂ OCH(CH ₃)CH ₂ CH ₃	C ₁₉ H ₃₂ NO ₃ Cl	C: 63.76/63.91 H: 9.01/9.01 N: 3.91/3.89	-52.1 c=1.0
	6	-CH ₂ CH ₂ O—	C ₂₀ H ₃₂ NO ₃ Cl	C: 64.94/65.19 H: 8.72/8.60 N: 3.79/3.68	-49.2 c=1.1

5

Example	R ₆	Elemental Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
7	-(CH ₂) ₂ O(CH ₂) ₂ CH ₃	C ₁₈ H ₃₀ NO ₃ Cl	C: 62.87/63.00 H: 8.79/8.99 N: 4.07/4.10	-53.0 c=1.4
8	-(CH ₂) ₂ O(CH ₂) ₃ CH ₃	C ₁₉ H ₃₂ NO ₃ Cl	C: 63.76/63.60 H: 9.01/9.11 N: 3.91/3.87	-52.5 c=1.1
9	-(CH ₂) ₂ OC(CH ₃) ₃	C ₁₉ H ₃₂ NO ₃ Cl	C: 63.76/63.80 H: 9.01/9.03 N: 3.91/4.03	-50.1 c=0.40
10	-(CH ₂) ₂ O(CH ₂) ₄ CH ₃	C ₂₀ H ₃₄ NO ₃ Cl	C: 64.58/64.70 H: 9.21/9.40 N: 3.77/3.97	-51.7 c=1.1
11		C ₁₉ H ₃₀ NO ₃ Cl	C: 64.12/63.85 H: 8.50/8.69 N: 3.94/3.67	-42.0 c=1.0
12		C ₂₀ H ₃₂ NO ₃ Cl	C: 64.94/64.73 H: 8.72/8.58 N: 3.79/3.68	-40.6 c=1.4
13	-(CH ₂) ₃ OCH(CH ₃) ₂	C ₁₉ H ₃₂ NO ₃ Cl	C: 63.76/63.60 H: 9.01/9.07 N: 3.91/3.89	-47.4 c=1.0
14		C ₁₉ H ₃₀ NO ₃ Cl	C: 64.12/63.86 H: 8.50/8.69 N: 3.94/3.82	-53.4 c=1.1
15		C ₁₈ H ₂₈ NO ₃ Cl	C: 63.24/63.18 H: 8.26/8.34 N: 4.10/3.92	-53.6 c=1.2

10

A similar procedure can be used to prepare compounds of the present invention wherein R₃ is H and R₂ is OH (general formula 2). This process is schematically described below (Method B), and in detail for Example #21.

Method B**Method B - Detailed Example****Preparation of (6S)-5,6,7,8-tetrahydro-6-[(tetrahydro-3-furanyl)methyl]propylamino-1-naphthalenol, hydrochloride (Example 21)**

5 A. (S)-5,6,7,8-Tetrahydro-6-propylamino-1-naphthalenol. (S)-6-Propylamino-5,6,7,8-tetrahydro-1-naphthalenol, hydrobromide (3.5 g, 0.0122 mol, prepared as in Example 1, part A) was partitioned between concentrated ammonium hydroxide and ether. The layers were separated and the aqueous layer was extracted with ether. The combined organic layers were washed twice with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate), filtered and concentrated to give 2.10 g of the free base (84% yield) as a white solid.

10 B. (6S)-5,6,7,8-tetrahydro-6-[(tetrahydro-3-furanyl)methyl]propylamino-1-naphthalenol, hydrochloride. A solution of tetrahydro-3-furanmethanol (0.37 g, 0.00362 mol) in methylene chloride (10 mL) was cooled in an ice-acetone bath with stirring under nitrogen. Diisopropylethylamine (0.94 g, 0.00727 mol) was added, followed by trifluoromethanesulfonic anhydride (1.03 g, 0.00365 mol). The mixture was stirred for ten minutes, then a solution of (S)-5,6,7,8-tetrahydro-6-propylamino-1-naphthalenol (0.75 g, 0.00366 mol) in methylene chloride (15 mL) was added dropwise. The mixture was stirred at room temperature

-19-

overnight. Water and ether were added, and the layers were separated. The ether layer was washed two times with water and once with a saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. Column chromatography of the residue on silica eluting with ethyl acetate-light pet ether (1:4) afforded the oily free base of the product. The oil was dissolved in ether and treated with ethereal hydrogen chloride. The mother liquor was decanted from the amorphous solid which separated (alternatively, the solid can be collected by filtration), and the solid was dried under vacuum at 50°C to give 0.43 g (36% yield) of product.

10 Table II summarizes compounds which are examples of the present invention prepared by Method B, in which R_2 is OH and R_3 is H:













Table II

Example	R ₅	R ₆	Empirical Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
16	-CH ₂ CH ₂ CH ₃	-(CH ₂) ₂ -O- 	C ₂₀ H ₃₂ NO ₂ Cl	C: 67.87/67.65 H: 9.11/8.90 N: 3.96/3.94	-52.9 (c=1.0)
17	-CH ₂ CH ₂ CH ₃	-(CH ₂) ₂ -O- 	C ₁₈ H ₂₈ NO ₂ Cl	C: 66.34/65.99 H: 8.66/8.44 N: 4.30/4.03	-59.1 (c=1.1)

Example	R ₅	R ₆	Empirical Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
18	-CH ₂ CH ₂ CH ₃	—(CH ₂) ₂ —O— 	C ₁₉ H ₃₀ NO ₂ Cl	C: 67.14/67.38 H: 8.90/8.99 N: 4.12/4.07	-56.4 (c=1.4)
19	-CH ₂ CH ₂ CH ₃	—CH ₂ CH ₂ — 	C ₁₉ H ₃₀ NO ₂ Cl (1/2 H ₂ O)	C: 65.41/65.06 H: 8.96/8.56 N: 4.01/3.96	-44.4 (c=1.0)
20	-CH ₂ CH ₂ CH ₃	—CH ₂ — 	C ₁₉ H ₃₀ NO ₂ Cl	C: 67.14/66.94 H: 8.90/8.76 N: 4.12/3.89	-52.9 (c=1.0)
21	-CH ₂ CH ₂ CH ₃	—CH ₂ — 	C ₁₈ H ₂₈ NO ₂ Cl	C: 66.34/66.25 H: 8.66/8.50 N: 4.30/4.19	-56.9 (c=1.0)
22	-CH ₂ CH ₂ CH ₃	—CH ₂ — 	C ₁₈ H ₂₈ NO ₂ Cl	C: 66.34/66.20 H: 8.66/8.39 N: 4.30/4.22	-55.9 (c=1.1)
23	-CH ₂ CH ₂ CH ₃	—CH ₂ CH ₂ — 	C ₂₀ H ₃₂ NO ₂ Cl	C: 67.87/67.83 H: 9.11/8.77 N: 3.96/3.86	-47.3 (c=1.0)
24	-CH ₂ CH ₂ CH ₃	—CH ₂ CH ₂ — 	C ₁₉ H ₃₀ NO ₂ Cl	C: 67.14/66.89 H: 8.90/8.69 N: 4.12/3.86	-52.4 (c=1.0)
25	-CH ₂ CH ₃	—CH ₂ CH ₂ — 	C ₁₈ H ₂₈ NO ₂ Cl	C: 66.34/66.27 H: 8.66/8.86 N: 4.30/4.10	-51.9 (c=1.0)

Compounds of the present invention wherein R_2 and R_3 are joined together to form the general structure (3) can be prepared as shown below (Method C). This process is described in detail for Example #26.

Method C



5

Method C - Detailed Example

Preparation of (S)-6,7,8,9-tetrahydro-N-[2-(1-methylethoxy)ethyl]-N-propylnaphtho[1,2-d]-1,3-dioxol-7-amine, hydrochloride (Example 26)

A. *(S)-N-(6,7,8,9-Tetrahydronaphtho[1,2-d]-1,3-dioxol-7-yl)-N-propylcarbamic acid, phenylmethyl ester.* To a stirred suspension of potassium hydroxide (0.68 g, 0.0121 mol) in dimethyl sulfoxide (30 mL) under nitrogen was added a solution of (S)-N-(1,2,3,4-tetrahydro-5,6-dihydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester (1.5 g, 0.00422 mol, prepared as in Example 1, part D) in dimethyl sulfoxide (30 mL). The mixture was heated to 80°C and dibromomethane (0.74 g, 0.00426

mol) was added. Heating was continued at 80°C overnight, then the mixture was poured into dilute aqueous hydrochloric acid (600 mL). The resulting suspension was extracted with two portions of ether. The combined ether extracts layers were washed twice with water, twice with aqueous 5% sodium hydroxide, twice again with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate), and concentrated. Column chromatography of the residue on silica eluting with ethyl acetate-light pet ether (1:9) afforded 1.14 g (74% yield) of product as a white solid.

B. (S)-6,7,8,9-Tetrahydro-N-propylnaphtho[1,2-d]-1,3-dioxol-7-amine. A solution of (S)-N-(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-7-yl)-N-propylcarbamic acid, phenylmethyl ester (1.14 g, 0.00311 mol) in tetrahydrofuran was shaken for one hour over 5% palladium on carbon under an initial pressure of 40 psi of hydrogen. The mixture was filtered to remove the catalyst, and the filtrate was concentrated. The oily product residue was used without additional purification.

C. (S)-6,7,8,9-Tetrahydro-N-[2-(1-methylethoxy)ethyl]-N-propylnaphtho[1,2-d]-1,3-dioxol-7-amine, hydrochloride. A solution of 2-(1-methylethoxy)ethanol (0.32 g, 0.00307 mol) in methylene chloride (10 mL) was cooled in an ice-acetone bath with stirring under a nitrogen atmosphere. Diisopropylethylamine (0.80 g, 0.00619 mol) followed by trifluoromethane-sulfonic anhydride (0.88 g, 0.00312 mol) were added and the solution was stirred for five minutes. A solution of (S)-6,7,8,9-tetrahydro-N-propylnaphtho[1,2-d]-1,3-dioxol-7-amine (0.00311 mol) in methylene chloride (20 mL) was added and the mixture was stirred at room temperature overnight. Water and ether were added and the layers were separated. The organic layer was washed two times with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. Column chromatography on the residue on silica eluting with ethyl acetate-light pet ether (1:9) afforded the free base of the product as a colorless oil. The oil was dissolved in ether and treated with ethereal hydrogen chloride. The solvent was removed by distillation under reduced pressure (optionally

decantation, or filtration) and the residue was dried under high vacuum at 40°C to give 0.29 g (26% yield) of product.

5

Table III summarizes compounds which are examples of the present invention prepared by Method C, in which R₂ and R₃ are joined together to form the following structure:





Table III

Example	R ₆	Empirical Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
26	-(CH ₂) ₂ OCH(CH ₃) ₂	C ₁₉ H ₃₀ NO ₃ Cl	C: 64.12/64.00 H: 8.50/8.59 N: 3.94/3.94	-38.7 (c=1.3)
27	-(CH ₂) ₂ OCH ₂ CH ₃	C ₁₈ H ₂₈ NO ₃ Cl	C: 63.24/63.00 H: 8.26/8.47 N: 4.10/3.98	-51.8 (c=1.2)
28	-(CH ₂) ₂ O(CH ₂) ₂ CH ₃	C ₁₉ H ₃₀ NO ₃ Cl	C: 64.12/63.95 H: 8.50/8.63 N: 3.94/3.84	-49.2 (c=1.2)
29	-(CH ₂) ₂ OC(CH ₃) ₃	C ₂₀ H ₃₂ NO ₃ Cl	C: 64.94/64.91 H: 8.72/8.57 N: 3.79/3.61	-41.6 (c=1.2)


Compounds of the present invention wherein A is:



(general formulae 4 and 5) can be prepared by the reaction of the phenolic compounds with an acyl chloride in the presence of a base as shown below

(Method D). This process is described in detail for Examples #30 (R_2 and $R_3=OA$) and #37 ($R_2=OA$, $R_3=H$).

Method D



Method D - Detailed Example

5

Preparation of (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol, diacetate (Example 30)

10

(S)-5,6,7,8-Tetrahydro-6-[[2-(1-methylethoxy)ethyl]propylamino]-1,2-naphthalenediol (0.38 g, 0.00122 mol, free base prepared as in Example 1) was dissolved in methylene chloride (20 mL) with stirring in an ice bath under a nitrogen atmosphere. Triethylamine (0.28 g, 0.00277 mol) and acetyl chloride (0.20 g, 0.00255 mol) were added sequentially. The mixture was stirred at room temperature for three days. Water and ether were added and the layers were separated. The organic layer was washed once with water,

once with aqueous saturated sodium bicarbonate, and once with aqueous saturated sodium chloride, then dried (magnesium sulfate) and concentrated. Column chromatography of the residue on silica eluting with ethyl acetate-light pet ether (2:3) gave 0.17 g (35% yield) of product.

5

Table IV summarizes compounds which are examples of the present invention prepared by Method D, in which R_2 and R_3 are OA, where A is :





Table IV

Example	R_4	R_6	Empirical Formula	Elemental Analysis (calc.:/obs.)	$[\alpha]_D$ (MeOH)
30	$-\text{CH}_3$	$-(\text{CH}_2)_2\text{OCH}(\text{CH}_3)_2$	$\text{C}_{22}\text{H}_{33}\text{NO}_5$	C: 67.49/67.39 H: 8.50/8.36 N: 3.58/3.41	-40.1 (c=0.73)
31	$-(\text{CH}_2)_4\text{CH}_3$	$-(\text{CH}_2)_2\text{OCH}(\text{CH}_3)_2$	$\text{C}_{30}\text{H}_{49}\text{NO}_5$	C: 71.53/71.71 H: 9.81/10.00 N: 2.78/2.69	-36.62 (c=1.0)
32	$-\text{CH}_3$	$-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2\text{CH}_3$	$\text{C}_{22}\text{H}_{33}\text{NO}_5$	C: 67.49/67.70 H: 8.50/8.30 N: 3.58/3.54	-46.9 (c=0.67)
33	$-\text{CH}_3$	$-(\text{CH}_2)_2\text{O}(\text{CH}_2)_3\text{CH}_3$	$\text{C}_{23}\text{H}_{35}\text{NO}_5$	C: 68.12/68.22 H: 8.70/8.52 N: 3.45/3.41	-44.4 (c=0.82)

Example	R ₄	R ₆	Empirical Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
35	-C(CH ₃) ₃	-(CH ₂) ₂ OCH(CH ₃) ₂	C ₂₈ H ₄₅ NO ₅	C: 70.70/70.80 H: 9.54/9.54 N: 2.94/3.01	-32.0 (c=1.0)
36	-C(CH ₃) ₃	-(CH ₂) ₂ OC(CH ₃) ₃	C ₂₉ H ₄₇ NO ₅	C: 71.13/70.89 H: 9.67/9.75 N: 2.86/2.87	-29.9 (c=1.5)

Method D - Detailed Example

Preparation of (6S)-5,6,7,8-tetrahydro-6-[[2-(tetrahydro-2-furanyl)ethyl]propylamino]-1-naphthalenol, decanoate (Example 37)

5 A solution of (6S)-5,6,7,8-tetrahydro-6-[[2-(tetrahydro-2-furanyl)ethyl]propylamino]-1-naphthalenol (0.4 g, 0.00132 mol, free base prepared as in Example 30) and triethylamine (0.15 g, 0.00148 mol) in methylene chloride was stirred under nitrogen. Decanoyl chloride (0.28 g, 0.00147 mol) was added and the mixture was stirred at room temperature overnight. Water and ether were added and the layers were separated. The aqueous layer was extracted three times with ether, and the combined organic layers were washed with saturated aqueous sodium bicarbonate and with saturated aqueous sodium chloride, dried (magnesium sulfate) and concentrated. Column chromatography of the residue on silica eluting with ethyl acetate-light pet ether (3:7) gave 0.180 g (30% yield) of product.

10

15 Table V summarizes an example of the present invention prepared by

Method D, in which R₂ is OA and R₃ is H, where A is: $\text{---C}(\text{=O})\text{---R}_4$

-27-





Table V

Example	R ₄	R ₆	Empirical Formula	Elemental Analysis (calc./obs.)	[α] _D (MeOH)
37	-(CH ₂) ₈ CH ₃		C ₂₉ H ₄₇ NO ₃	C: 76.10/75.85 H: 10.35/10.04 N: 3.06/3.02	-38.4 (c=1.0)

Compounds of the present invention wherein R₂ and R₃ are joined together to form the general structure (6) can be prepared as shown below (Method E). This process is described in detail in Example #38.

Method E



Method E - Detailed Example

Preparation of (S)-5,6,7,8-tetrahydro-6-[[2-(1-methylethoxy)-ethyl]propylamino]-1,2-naphthalenediol, cyclic carbonate, hydrochloride (Example #38)

5

10

A. (S)-N-(6,7,8-tetrahydro-2-oxonaphtho[1,2-d]-1,3-dioxol-7-yl)-N-propylcarbamic acid, phenylmethyl ester. A solution of (S)-N-(1,2,3,4-tetrahydro-5,6-dihydroxy-2-naphthalenyl)-N-propylcarbamic acid, phenylmethyl ester (2.0 g, 0.00563 mol), phosgene (2.79 g of a 20% solution in toluene, 0.00558 mol) and triethylamine (1.70 g, 0.0168 mol) in methylene chloride (100 mL) was stirred overnight under nitrogen. The mixture was heated at reflux for one hour, cooled to room temperature, then water and ether were added. The layers were separated and the organic layer was washed twice with water and once with saturated aqueous sodium chloride,

dried (magnesium sulfate), treated with charcoal, and filtered. The filtrate was concentrated. Column chromatography of the residue on silica eluting with ethyl acetate-light pet ether (1:4) gave 1.04 g (49% yield) of product.

B. (S)-5, 6, 7, 8-Tetrahydro-6-propylamino-1, 2-naphthalen diol, cyclic carbonate. A solution of (S)-N-(6,7,8,9-tetrahydro-2-oxonaphtho[1,2-d]-1,3-dioxol-7-yl)-N-propylcarbamic acid, phenylmethyl ester (1.14 g, 0.00311 mol) in tetrahydrofuran was shaken for three hours over 5% palladium on carbon under an initial pressure of 40 psi of hydrogen. The mixture was filtered to remove the catalyst, and the filtrate was concentrated. The oily product residue was used without additional purification.

C. (S)-5, 6, 7, 8-Tetrahydro-6-[2-(1-methylethoxy)ethyl]-propylamino]-1,2-naphthalenediol, cyclic carbonate, hydrochloride. A solution of 2-(1-methylethoxy)ethanol (0.27 g, 0.00259 mol) in methylene chloride (10 mL) was stirred in an ice-acetone bath under a nitrogen and diisopropylethylamine (0.68 g, 0.00526 mol) followed by trifluoromethane-sulfonic anhydride (0.74 g, 0.00262 mol) were added. The solution was stirred for ten minutes and a solution of (S)-5,6,7,8-Tetrahydro-6-propylamino-1,2-naphthalen diol, cyclic carbonate (0.00262 mol) in methylene chloride (10 mL) was added. The mixture was stirred overnight at room temperature. Water and ether were added and the layers were separated. The organic layer was washed once with water and once with saturated aqueous sodium chloride, dried (magnesium sulfate), filtered and concentrated. Column chromatography of the residue on silica eluting with ethyl acetate-light pet ether (1:4) gave the oily free base of the product. The oil was dissolved in ether and treated with ethereal hydrogen chloride and the solvent was removed under reduced pressure. The residual glass was washed twice with ether and the washings were decanted. Drying under high vacuum at 50°C overnight gave 0.23 g (24% yield) of product.

Table VI summarizes an example of the present invention prepared by Method E, in which R_2 and R_3 are joined together to form the following structure:




Table VI

Example	R_6	Empirical Formula	Elemental Analysis (calc./obs.)	$[\alpha]_D$ (MeOH)
38	$-(CH_2)_2OCH(CH_3)_2$	$C_{19}H_{28}NO_4Cl$	C: 61.70/61.49 H: 7.63/7.80 N: 3.79/3.65	-49.8 (c=0.57)

Pharmacological Testing of Exemplified Compounds

5 Pharmacological test methods are described below. The compounds of the present invention were tested for dopaminergic activity, with results being summarized in the accompanying tables. These data were generated to provide measures of the compounds' selectivity (D_2/D_1) for dopamine D₂ receptors, dopamine D₂ receptor in vitro functional potency and specificity (D_2/α_2), as well as dopamine D₂ receptor in vivo functional potency. Test results for comparative examples in the prior art [see McDermed et al, J. Med. Chem., 19, 547 (1976); McDermed, et al, J. Med. Chem., 18, 362 (1975); Seiler, et al, J. Med. Chem., 29, 912 (1986)] are included for reference purposes [Example 39: 5-hydroxy-2-(di-n-propyl)aminotetralin, Example 40: (S)-5,6-dihydroxy-2-(di-n-propyl)aminotetralin, Example 41: (S)-5,6,7,8-tetrahydro-6-[(3-methoxypropyl)propylamino]-1-naphthalenol].

1. *Receptor Affinity Experiments (Radioligand Binding)*

Membranes were prepared using a Brinkmann Polytron and collected by centrifugation. Membrane sources were bovine caudate (D_2, D_1) or rat cortex (α_2). The membranes were washed, resuspended, and incubated at 37°C for 30 min. in either the presence (rat cortex) of 1 U/ml adenosine deaminase or absence (bovine caudate) of 0.1 U/ml adenosine deaminase. Membranes were centrifuged, washed once and frozen at -70°C until used. Immediately before use, the membranes were thawed, washed once, and resuspended to a final concentration of 0.5-2 mg/ml. Assays were initiated by addition of membranes. For D_2 and D_1 assays, the radioligands and conditions used were ^3H -Spiperone (RT, 75 min.) and ^3H -SCH23390 (37°C, 15 min.), respectively. For α_2 assays, ^3H -PAC (RT, 30 min.) was used. Assays were terminated by filtration using a Brandel cell harvester over Whatman GF/B filters that had been pretreated with 0.1% polyethylenimine. The filters were counted in either a Beckman LS 3801 or TD 5000 scintillation counter. Data were analyzed using the Ligand program [Munson, P. and Rodbard, D., Analytical Biochemistry, 107, 220-239 (1980)]. The results are expressed in Table VII below:

Table VII

**Dopamine D₂ and D₁ Receptor Affinity
and Resultant Selectivity Ratio**

Example	D ₂ K _i (μ M)	D ₁ K _i (μ M)	Selectivity Ratio (D ₁ K _i /D ₂ K _i)
	0.065	7.24	112
5	0.316	6.31	20
	0.065	4.79	74
	0.363	7.08	19
	0.115	4.57	40
	0.051	5.01	98
10	0.129	4.68	36
	0.112	5.89	52
	0.054	8.91	166
	0.054	2.45	46
	0.030	4.27	141
15	0.025	5.49	224
	0.051	5.75	113
	0.195	6.61	34
	1.100	1.100	1
	0.062	7.94	129
20	0.468	9.77	21
	0.200	8.91	45
	0.110	1.51	14
	1.070	7.08	7
	0.151	3.63	24
25	1.510	16.2	11
	0.110	7.41	68
	0.263	5.62	21
	0.117	6.61	57
	0.790	3.80	5
30	0.115	1.29	11
	0.790	11.0	14

These data show the high degrees of dopamine D₂ receptor affinity and selectivity achieved with compounds of the current invention.

2. *Dopamine - D₂ In Vitro Functional Test*

Vasa deferentia from male BALB/C mice weighing approximately 30 g were removed and placed in isolated organ baths containing magnesium-free modified Krebs-Henseleit solution which was gassed with 95% O₂ and 5% CO₂ and maintained at 37°C. Tissues were set up under resting tension of 0.5g and stimulated electrically at 60 volts, 0.1 Hz and 1 msec duration to produce a series of twitch responses. Tissues were pretreated with propranolol (1 μ M) to block β -adrenoceptors, idazoxan (3 μ M) to block α_2 -adrenoceptors receptors, and ascorbic acid (100 μ M) for 60 min before the addition of test compound. The potency of the test compound is expressed as the concentration that produces 50% of the maximal inhibition of twitch. These results are summarized in Table VIII below.

10
15
20

3. *Adrenergic - α_2 In Vitro Functional Test*

Vasa deferentia from male Sprague-Dawley rats weighing between 150-250g were removed and placed in isolated organ baths containing Krebs-Henseleit solution under a resting tension of 1g. All other set up conditions were identical to those used for the mouse vas deferens. Tissues were pretreated with propranolol (1 μ M), ascorbic acid (100 μ M) and the α_1 -adrenergic antagonist prazosin (0.3 or 1 μ M) for 60 min before the addition of test compound. The potency of the test compound is expressed as the concentration that produces 50% of the maximal inhibition of twitch. These results are summarized in Table VIII below.

Table VIII

**Functional Potencies at D_2 , α_2 Receptors
and Resultant Specificity Ratio**

Example	$D_2 A_{50}$ (nM)	$\alpha_2 A_{50}$ (nM)	Specificity Ratio ($\alpha_2 A_{50}/D_2 A_{50}$)
	0.148	218	1480
5	0.417	18.6	45
	0.105	195	1860
	0.603	42.7	71
	0.240	245	1020
	0.162	87.1	537
10	0.794	148	186
	0.269	107	398
	0.089	144	1620
	0.093	93.3	1000
	1.290	79.4	62
15	0.200	199	1000
	0.102	93.3	914
	0.209	14.8	71
	0.141	16.6	118
	0.513	> 10000	> 19500
20	0.589	> 10000	> 17000
	0.676	> 10000	> 14800
	0.275	1740	6310
	1.000	190	191
	0.977	275	282
25	2.190	3550	1620
	0.437	> 10000	> 22900
	0.776	123	158
	0.708	> 10000	> 14100
	2.140	257	120
30	0.250	12.5	50
	0.910	234	257

These data show the high degrees of dopamine D_2 receptor in vitro functional activity and specificity (D_2 vs. α_2). See U.S. Patent No.

-35-

5,068,325, which explains the importance of high degrees of D_2 vs. α_2 specificity.

4. *In Vivo Functional Test*

5 Dopamine agonists produce contralateral circling behavior in rats in which unilateral lesions of the substantia nigra are made by prior injection of 6-hydroxydopamine. The circling is thought to be mediated by stimulation of denervated supersensitive postsynaptic dopamine receptors (Marshall and Ungerstedt, 1977, Eur. J. Pharmacol., 41:361-367). The method of Van der Werf, et al. (Eur. J. Pharmacol., 102:387-399) was used, and the results are

10 summarized in Table IX below.

Table IX
In Vivo Functional Potencies


	Example	ED ₅₀ (μ mol/kg)
5	1	0.004
	2	0.004
	3	0.007
	4	0.006
	5	0.006
	6	0.008
10	7	0.002
	8	0.004
	9	0.004
	10	0.030
	11	0.010
	12	0.030
15	13	0.006
	14	0.030
	15	0.009
	16	0.090
	17	0.009
	18	0.020
20	19	0.020
	20	0.030
	21	0.009
	22	0.030
	23	0.010
	24	0.020
25	25	N/A
	26	0.030
	27	0.100
	28	0.100
	29	0.040
	38	0.005
30	39	0.010
	40	0.009
	41	0.020

These data show the high degrees of dopamine D₂ receptor functional potencies achieved with the compounds of the present invention.


What Is Claimed Is:

Having now described the invention, I claim:

1. Optically active or racemic compounds represented by the formula:




5 wherein R₁ is selected from the group consisting of alkoxy, cycloalkoxy and a cyclic ether of the formula




where m is an integer between 3 and 5;

10 R₂ is OA; R₃ is selected from the group consisting of H and OA; where A is H or is selected from the group consisting of hydrocarbyl radicals having from 1 to 3 carbon atoms,



the proviso that when R₁ is alkoxy, then R₃ cannot be H, and with the further proviso that when both R₂ and R₃ are OA, and R₃ are OA, then R₂ and R₃ may be bonded together to form the group $\text{---O---CH}_2\text{---O---}$



5 R_4 is selected from the group consisting of hydrocarbyl radicals having from 1 to 20 carbon atoms; n is an integer from 1 to 4; and R_5 is an unbranched alkyl chain having from 1 to 3 carbon atoms or a cyclopropylmethyl radical.

2. The compounds of claim 1 wherein A is H.

10 3. The compounds of claim 1 wherein A is selected from the group consisting of hydrocarbyl radicals having from 1 to 3 carbon atoms.

4. The compounds of claim 1 wherein A is selected from the group

15 consisting of ---C=O---R_4 , ---C=O---NHR_4 , $\text{---C=O---N(R}_4)_2$, and
 ---C=O---OR_4 .

5. The compounds of claim 4 wherein R_4 is selected from the group consisting of alkyl radicals.

20 6. The compounds of claim 2 wherein R_1 is selected from the group consisting of ethoxy, propoxy, isopropoxy, n-butoxy, t-butoxy, s-butoxy, isobutoxy, and tetrahydro-3-furanyl.

7. The compounds of claim 2 wherein R_3 is H.

8. The compounds of claim 2 wherein R_3 is OA.

9. The compounds of claim 8 wherein A is selected from the group

5 consisting of H, $\text{C}(=\text{O})\text{R}_4$, $\text{C}(=\text{O})\text{NHR}_4$, $\text{C}(=\text{O})\text{N}(\text{R}_4)_2$, and
 $\text{C}(=\text{O})\text{OR}_4$.

10. The compounds of claim 8 wherein R_2 and R_3 are taken together

10 to form the group $\text{O}-\text{CH}_2-\text{O}$ or $\text{O}-\text{C}(=\text{O})-\text{O}$.


11. The compounds of claim 6 wherein n is 2.

12. The compounds of claim 11 wherein R_3 is OA.


13. The compounds of claim 12 wherein R_1 is selected from the
 15 group consisting of isopropoxy and t-butoxy.

14. The compounds of claim 13 wherein the optically active compound is the S-enantiomer.

20 15. A method for inducing a dopaminergic response in a mammal comprising administering to said mammal an effective amount of a compound selected from the group consisting of a compound represented by the formula



wherein R₁ is selected from the group consisting of alkoxy, cycloalkoxy and a cyclic ether of the formula



where m is an integer between 3 and 5;

R₂ is OA; R₃ is selected from the group consisting of H and OA; where A is H or is selected from the group consisting of hydrocarbyl radicals having from 1 to 3 carbon atoms,

—C=O—R₄, —C=O—NHR₄, —C=O—N(R₄)₂, and —C=O—OR₄ with

the proviso that when R₁ is alkoxy, then R₃ cannot be H, and with the further proviso that when both R₂ and R₃ are OA, then R₂ and R₃ may be bonded together to form the group —O—CH₂—O— or


15 —O—C=O—O— ;

R₄ is selected from the group consisting of hydrocarbyl radicals having from 1 to 20 carbon atoms; n is an integer of 1 to 4; and R₅ is an unbranched alkyl chain having from 1 to 3 carbon atoms or a cyclopropylmethyl radical.

-41-


16. The method of claim 15 wherein R_3 is H.

17. The method of claim 15 wherein R_3 is OA, and A is selected



18. The method of claim 17 wherein R_4 is selected from the group of alkyl radicals.

19. The method of claim 17 wherein R_1 is selected from the group consisting of alkoxy, cycloalkoxy and a cyclic ether of the formula



10 where m is an integer from 3 to 5.

20. The method of claim 19 wherein n is 2.

21. The method of claim 20 wherein R_1 is selected from the group consisting of isopropoxy and t-butoxy.

22. The method of claim 21 wherein the optically active compound
15 is the S-enantiomer.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08845

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A, 4,410,519 (Seiler et al.) 18 October 1983, see entire document.	1-22
A	US, A, 4,564,628 (Horn) 14 January 1986, see entire document.	1-22
A	US, A, 4,722,933 (Horn) 02 February 1988.	1-22
A	Journal of Medicinal Chemistry, Volume 22, No. 12, issued 1979, Uli Hacksell et al, "N-Alkylated 2-Aminotetralins: Central Dopamine-Receptor Stimulating Activity", pages 1469-1475.	1-22

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
05 OCTOBER 1994Date of mailing of the international search report
04 JAN 1995Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

CECILIA TSANG

Facsimile No. (703) 305-3230

Telephone No. (703)308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08845

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 31/34, 31/35, 31/335, 31/38, 31/275, 31/655; C07D 317/44, 315/00, 307/02; C07C 211/00, 117/00, 229/00, 69/00.

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

514/ 357, 415, 427, 438, 459, 463, 471, 521, 523; 549/426, 439, 492, 495; 560/43, 59, 61, 110, 133, 138, 139, 250, 251; 564/167, 308, 428.

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/ 357, 415, 427, 438, 459, 463, 471; 549/426, 439, 492, 495; 560/27, 43, 59, 61, 110, 133, 138, 139, 250, 255; 564/56, 86, 167, 308, 428.